How are earnouts measured in a dental practice sale?

An earnout pays out when the practice hits a performance metric — usually EBITDA, sometimes collections — measured over three to five years after closing. The critical fact most sellers miss is that the buyer controls the levers producing that metric (staffing, scheduling, payer strategy, overhead allocation) and, unless the purchase agreement says otherwise, controls how it is measured. If EBITDA is left undefined, the platform can allocate corporate overhead down to the practice — a 5% management fee, centralized billing, recruiting, IT — and a practice that performed identically can miss its target on accounting alone.

What is a seller-structured earnout?

A seller-structured earnout defines five things the buyer's default paper leaves open: the measurement basis (EBITDA on the same basis as the closing model, corporate allocations excluded or capped at the diligence assumption), reporting and audit rights (monthly P&L, right to audit, a named independent accountant for disputes), pro-rata payment with cumulative catch-up instead of an all-or-nothing cliff, lever covenants that adjust the target if the buyer changes payer mix, marketing spend, or provider headcount, and protection clauses covering a platform sale, termination without cause, and indemnity offsets.

Why do dental practice earnouts fail to pay out?

Rarely because of fraud or breach — usually because of discretion exercised by the side holding the pen. Overhead allocated down at unbenchmarked rates, centralized services billed at unaudited cost, a visiting specialist's 50/50 collections split replaced by the platform's internal specialist whose compensation lands on the practice P&L, a remodel scheduled during the measurement year, or network participation changes that raise volume while lowering realization. Each is defensible in isolation and invisible unless the agreement provides the reporting rights to see it and the definition language to challenge it.

Where do earnouts come from in a DSO deal?

Two origins, one instrument. First, transition insurance: buyers price where the practice is going, and the most critical variable in that forecast is the owner — the earnout exists to make sure the business survives the person the buyer is purchasing it from. Second, diligence findings: when the buyer's Quality of Earnings team finds a soft add-back or provider dependency, it converts certainty into contingency rather than cutting the headline price. That is why earnouts typically run 10-30% of the deal, and why the sellers carrying the largest ones are those whose practices depended on them most or whose numbers could not fully defend themselves.

Should an earnout be tied to EBITDA or collections?

A collections-based target is materially harder for a buyer to move through accounting discretion — management fees and overhead allocations do not touch collections. It exposes the seller to top-line levers instead (payer mix, marketing spend, provider changes), so lever covenants still matter. An EBITDA-based target requires the full measurement-basis definition to be safe. Whichever metric is used, the same rule governs: the target is the headline, and the definition is what actually gets paid.

Financial Analytics

The Moving Target: How Dental Practice Earnouts Are Measured and Controlled

James DeLuca August 31, 2026 9 min read

Last week I wrote about the unseen earnout clause and said the definition is the deal. This article is the proof, and here is the sentence that should reframe how you read every offer:

An earnout is not a number. It is a measurement system you will live inside for three to five years, administered by the other side.

Where Earnouts Actually Come From

Sellers imagine the earnout as a valuation bridge: the buyer believes in the practice slightly less than you do, so you split the difference over time. That’s the flattering version, and it’s mostly wrong.

Buyers are not pricing where your practice has been. They are forecasting where it goes next — underwriting the next million, not the last one. And in that forecast, the single most critical variable is you: the owner whose name, hands, and habits the earnings were built around. The earnout exists to answer the question every buyer’s model asks before it prices anything: does this business survive the person we’re buying it from?

Read that way, the structure explains itself. The earnout is not a compromise on price; it is transition insurance. In a practice transition, the owner is both the risk being insured and the collateral securing it. The more the practice depends on you, the more of your money gets converted into that policy. This is key-person risk priced in terms, not multiples.

The other birthplace is diligence. The buyer’s Quality of Earnings team finds something — soft add-backs, provider dependency, revenue that doesn’t verify — and instead of cutting the price outright, they convert certainty into contingency. The price survives the press release, and what died was your guarantee of receiving it.

Two origins, one instrument: transition risk and diligence findings both get resolved by moving your money from certain to contingent. That is why earnouts typically run 10–30% of the deal, and why the sellers carrying the largest ones are precisely the sellers whose practices depended on them most, or whose numbers couldn’t fully defend themselves.

The Mechanics, in Dollars

Run the example from last week. You defended your number: $1.5M of EBITDA at 7×, a $10.5M deal, 20% as an earnout — $2.1M payable if the practice holds its EBITDA for three years.

On the buyer’s paper, “EBITDA” is undefined. Post-close, the platform allocates overhead down to your practice: a 5% management fee, centralized billing, recruiting, IT. On $5M of collections, that’s $250K of new “expense” the practice never carried. Your operation didn’t change. Your measured EBITDA is now $1.25M. Target missed. Earnout: $0.

	Closing model	Post-close measurement
Collections	$5,000,000	$5,000,000
Practice EBITDA	$1,500,000	$1,500,000
Corporate allocation (5% management fee, billing, recruiting, IT)	—	−$250,000
Measured EBITDA	$1,500,000	$1,250,000
Earnout target	$1,500,000	$1,500,000
Earnout paid	$2,100,000	$0

Source: Precision Dental Analytics earnout model. Same practice, same performance — the only variable is the definition of EBITDA.

Nothing was mismanaged. Nothing was breached. The definitions did all of the work.

The Five Clauses That Decide Who Wins

When I say “negotiate the definition,” here is specifically what that means.

1. The measurement basis. The earnout EBITDA must be measured on the same basis as the closing model — the same accounting policies, the same treatment of add-backs, corporate allocations excluded or capped at whatever the buyer’s own diligence model assumed. If their model didn’t charge your practice a management fee when they priced it, their measurement shouldn’t charge one when they grade it.

2. Reporting and audit rights. Monthly P&L for the earnout entity, delivered on a defined schedule. The right to audit the calculation. A named independent accountant to resolve disputes. Trust is not a dispute mechanism, and by year two the person who shook your hand may have changed jobs.

3. Pro-rata, not cliff. An all-or-nothing target is a trap: miss by 2% and lose 100%. Structure pro-rata payment against performance, with a cumulative catch-up. If a bad year is followed by two strong ones, it should still pay.

4. Lever covenants. After closing, the buyer controls the levers that produce your metric — overhead, scheduling, and payer strategy. And understand what the payer lever actually looks like: in a fee-for-service rollup, no DSO is interested in charging less. The platform may, however, forecast that joining specific insurance networks increases foot traffic and is beneficial over their five-year horizon. Your measurement window is three. Patient volume rises, realization falls as every new patient arrives with a contractual write-off attached, while staffing and supply costs scale with the traffic.

At the platform level, over their timeline, it may be exactly the right call. Measured against your earnout window, it’s margin compression you didn’t choose and can’t veto. “Commercially reasonable efforts” language protects against none of this — it’s the phrase lawyers settle on when nothing is defined. Name the levers: if network participation changes from the closing-date payer mix, if marketing drops below the diligence assumption, if provider headcount is cut, then the target adjusts, or the metric gets normalized back to closing-basis economics.

5. Protection clauses. Three scenarios nobody discusses at the LOI dinner: the platform sells itself during your earnout window (what happens to your metric under the new owner?); you’re terminated without cause before the measurement period ends (the earnout should accelerate or be deemed earned); and indemnity offsets (can the buyer subtract disputed claims from your earnout while you argue about them?).

All five clauses govern only the earnout. If your deal also includes rollover equity, you now own a second contingent instrument with entirely different failure modes, starting with dilution.

The Games

None of what follows is fraud. It is discretion, exercised by the side holding the pen. Overhead allocated down at rates no one benchmarked. Centralized services billed to your practice at “cost” nobody audited. A remodel scheduled during your measurement year. High-margin procedures or team members routed to a sister location. Revenue recognition that drifts just past the measurement date.

Here is one that will feel familiar. Many practices host a visiting specialist — an endodontist or oral surgeon in the operatory one day a month, on a 50/50 collections split. Under your ownership, that is one of the highest-margin days on your calendar: the specialist’s cost scales perfectly with what the day produces, and the practice keeps half of everything on minimal added overhead.

Now run the same day inside the rollup. The platform has its own internal specialist, so the visiting arrangement ends, and the specialist’s compensation, their team, and their supplies land on your practice’s P&L as allocated cost — produced or not. The exact same day, accounted differently, and the day that used to pull your EBITDA margin up by a few points no longer does. Two margin points on $5M of collections is $100,000 of measured EBITDA, every year of the measurement period. The operating model changed, your metric absorbed it, and a target set under the old accounting quietly became unreachable under the new one.

That is precisely what clause one exists for: measured on the same basis as the closing model. The buyer priced your practice with the 50/50 economics in it, and those economics still apply when it’s graded.

Each of these is defensible in isolation. Each is invisible unless your agreement gave you the reporting rights to see it and the definition language to challenge it.

Where the Leverage Actually Comes From

The leverage in this negotiation is not rhetorical. It is evidentiary. A seller demanding same-basis measurement, audit rights, and lever covenants is making a claim: my number is real, my practice transfers, and I am willing to be graded on it. That claim only carries weight when the data behind it has already been proven — a defensible EBITDA that survived a sell-side audit, and dependency metrics that show the practice runs without you.

Clean data works both directions at once. It arms your advisory team with the ammunition to negotiate seller-structured terms. And it gives the buyer confidence in the transition window, which is the actual thing the earnout exists to insure. Follow that logic to its end: a buyer who trusts the transition needs less insurance. Less insurance means a smaller earnout, more cash at close, and a definition you can live inside for whatever contingency remains.

You don’t negotiate your way out of a bad earnout. You audit your way out of one, years earlier, by remediating the two risks the instrument exists to price: the number, and the key person.

The Bottom Line

If there is an earnout in your deal — and at institutional multiples, there almost always is — the definition of how the metric is measured, who reports it, and who audits it decides what you actually collect. But the standing to demand that definition is earned years earlier, and it is verifiable in the data.

The target is the headline. The definition is the deal. The data is the leverage.

Frequently Asked

Questions

How are earnouts measured in a dental practice sale?: An earnout pays out when the practice hits a performance metric — usually EBITDA, sometimes collections — measured over three to five years after closing. The critical fact most sellers miss is that the buyer controls the levers producing that metric (staffing, scheduling, payer strategy, overhead allocation) and, unless the purchase agreement says otherwise, controls how it is measured. If EBITDA is left undefined, the platform can allocate corporate overhead down to the practice — a 5% management fee, centralized billing, recruiting, IT — and a practice that performed identically can miss its target on accounting alone.
What is a seller-structured earnout?: A seller-structured earnout defines five things the buyer's default paper leaves open: the measurement basis (EBITDA on the same basis as the closing model, corporate allocations excluded or capped at the diligence assumption), reporting and audit rights (monthly P&L, right to audit, a named independent accountant for disputes), pro-rata payment with cumulative catch-up instead of an all-or-nothing cliff, lever covenants that adjust the target if the buyer changes payer mix, marketing spend, or provider headcount, and protection clauses covering a platform sale, termination without cause, and indemnity offsets.
Why do dental practice earnouts fail to pay out?: Rarely because of fraud or breach — usually because of discretion exercised by the side holding the pen. Overhead allocated down at unbenchmarked rates, centralized services billed at unaudited cost, a visiting specialist's 50/50 collections split replaced by the platform's internal specialist whose compensation lands on the practice P&L, a remodel scheduled during the measurement year, or network participation changes that raise volume while lowering realization. Each is defensible in isolation and invisible unless the agreement provides the reporting rights to see it and the definition language to challenge it.
Where do earnouts come from in a DSO deal?: Two origins, one instrument. First, transition insurance: buyers price where the practice is going, and the most critical variable in that forecast is the owner — the earnout exists to make sure the business survives the person the buyer is purchasing it from. Second, diligence findings: when the buyer's Quality of Earnings team finds a soft add-back or provider dependency, it converts certainty into contingency rather than cutting the headline price. That is why earnouts typically run 10-30% of the deal, and why the sellers carrying the largest ones are those whose practices depended on them most or whose numbers could not fully defend themselves.
Should an earnout be tied to EBITDA or collections?: A collections-based target is materially harder for a buyer to move through accounting discretion — management fees and overhead allocations do not touch collections. It exposes the seller to top-line levers instead (payer mix, marketing spend, provider changes), so lever covenants still matter. An EBITDA-based target requires the full measurement-basis definition to be safe. Whichever metric is used, the same rule governs: the target is the headline, and the definition is what actually gets paid.